Business Description
Evolent Health Inc
NAICS : 621999
SIC : 8099
ISIN : US30050B1017
Share Class Description:
FRA:9EH: Class ATotal Employee Number:
4,200Description
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.14 | |||||
Equity-to-Asset | 0.21 | |||||
Debt-to-Equity | 2.49 | |||||
Debt-to-EBITDA | -3.09 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -0.41 | |||||
Beneish M-Score | -3.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.4 | |||||
3-Year EPS without NRI Growth Rate | -54.4 | |||||
3-Year Book Growth Rate | -24.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 79.28 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.81 | |||||
9-Day RSI | 53.07 | |||||
14-Day RSI | 57.52 | |||||
3-1 Month Momentum % | 60.32 | |||||
6-1 Month Momentum % | 19.53 | |||||
12-1 Month Momentum % | -58.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.32 | |||||
Quick Ratio | 1.32 | |||||
Cash Ratio | 0.37 | |||||
Days Sales Outstanding | 69.56 | |||||
Days Payable | 15.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.7 | |||||
Shareholder Yield % | -40.39 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 20.18 | |||||
Operating Margin % | -1.61 | |||||
Net Margin % | -26.29 | |||||
EBITDA Margin % | -16.88 | |||||
FCF Margin % | 0.04 | |||||
OCF Margin % | 1.72 | |||||
ROE % | -71.23 | |||||
ROA % | -21.88 | |||||
ROIC % | -1.47 | |||||
3-Year ROIIC % | -28.66 | |||||
ROC (Joel Greenblatt) % | -419.88 | |||||
ROCE % | -24.4 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 30.25 | |||||
PS Ratio | 0.35 | |||||
PB Ratio | 1.65 | |||||
Price-to-Free-Cash-Flow | 232.4 | |||||
Price-to-Operating-Cash-Flow | 19.05 | |||||
EV-to-EBIT | -3.46 | |||||
EV-to-Forward-EBIT | 17.41 | |||||
EV-to-EBITDA | -4.7 | |||||
EV-to-Forward-EBITDA | 18.42 | |||||
EV-to-Revenue | 0.79 | |||||
EV-to-Forward-Revenue | 0.6 | |||||
EV-to-FCF | 1073.06 | |||||
Price-to-GF-Value | 0.52 | |||||
Price-to-Projected-FCF | 1.79 | |||||
Price-to-Median-PS-Value | 0.18 | |||||
Earnings Yield (Greenblatt) % | -28.9 | |||||
FCF Yield % | 0.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evolent Health Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,623.333 | ||
| EPS (TTM) (€) | -4.072 | ||
| Beta | 1.796 | ||
| 3-Year Sharpe Ratio | -0.34 | ||
| 3-Year Sortino Ratio | -0.52 | ||
| Volatility % | 109.61 | ||
| 14-Day RSI | 57.52 | ||
| 14-Day ATR (€) | 0.160117 | ||
| 20-Day SMA (€) | 4.746 | ||
| 12-1 Month Momentum % | -58.78 | ||
| 52-Week Range (€) | 1.89 - 9.65 | ||
| Shares Outstanding (Mil) | 112.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evolent Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evolent Health Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 110 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 109 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | In 18 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 17 days | ||
| General meeting for 2026 | 2026-06-04 10:00 | 3.38 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 3.30 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.30 (+0.00%) | ||
| Oppenheimer 36 Annual Healthcare MedTech and Services Conference | 2026-03-17 10:00 | 2.60 (+0.00%) | ||
| Cowen 46 Annual Healthcare Conference | 2026-03-03 10:30 | 2.76 (+0.00%) | ||
| Annual report for 2025 | 2026-02-25 | 2.32 (+0.00%) |
Show
Entries
Evolent Health Inc Frequently Asked Questions
What is Evolent Health Inc(FRA:9EH)'s stock price today?
The current price of FRA:9EH is €4.90. The 52 week high of FRA:9EH is €9.65 and 52 week low is €1.89.
When is next earnings date of Evolent Health Inc(FRA:9EH)?
The next earnings date of Evolent Health Inc(FRA:9EH) is 2026-08-06.
Does Evolent Health Inc(FRA:9EH) pay dividends? If so, how much?
Evolent Health Inc(FRA:9EH) does not pay dividend.
Press Release
Articles on Evolent Health Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers